Syai Health secured significant funding from AstraZeneca plc & Xiaomi Corporation.SINGAPORE, Feb. 20, 2024 /PRNewswire/ -- Singapore-based biotech company, Syai Health, abbreviated for 'Sychronise + AI', secured significant funding from leading investors like AstraZeneca plc and Xiaomi Corporation for its in-house developed AI-empowered medical devices.

Syai Health获得了阿斯利康公司和小米公司的大量资金。新加坡，2024年2月20日/PRNewswire/--总部位于新加坡的生物技术公司Syai Health，缩写为“Sychronise+AI”，获得了阿斯利康（AstraZeneca plc）和小米（Xiaomi Corporation）等领先投资者的大量资金，用于其内部开发的人工智能医疗设备。

Originally an Oxford-Cambridge spinoff, alongside an R&D crew from top institutions and a design team from the Royal College of Art, Syai Health achieved another crucial fundraising milestone after years of dedication. Driven by a strong faith in transforming the industry (CDM), Syai's cutting-edge products, such as Continuous Glucose Monitor, promise to revolutionize home-based health management with a next-level digitalization.

Syai Health最初是牛津剑桥大学的分支机构，与顶尖机构的研发团队和皇家艺术学院的设计团队一起，经过多年的奉献，实现了另一个至关重要的筹资里程碑。在对改变行业（CDM）的坚定信念的推动下，Syai的尖端产品，如连续血糖监测仪，有望通过下一步的数字化彻底改变家庭健康管理。

Syai Health is prepared to broaden the horizon and reshape the CGM experience with its user-centric product lineup empowered by AI integration..

Syai Health准备通过AI集成提供的以用户为中心的产品阵容，拓宽视野，重塑CGM体验。。

Continue Reading

继续阅读

Syai Tag CGM with cross-platform functionality.

具有跨平台功能的Syai标签CGM。

Syai has distinguished itself in the market with its thoughtful design and data processing capabilities. The all-in-one monitoring unit can be worn discreetly on the body with its size of less than a quarter and weight of only 1.6g. Syai integrates its advanced algorithm that not only analyzes real-time glucose readings but also provides personalized feedback as a reference, making the device a responsive, considerate companion to users' health management journey.

Syai凭借其周到的设计和数据处理能力在市场上脱颖而出。一体式监控单元的尺寸不到四分之一，重量仅为1.6克，可以谨慎地佩戴在身体上。Syai集成了其先进的算法，不仅可以分析实时血糖读数，还可以提供个性化的反馈作为参考，使该设备成为用户健康管理旅程中响应迅速、体贴周到的伴侣。

It unlocked the potential for proactive users to make informed changes to their lifestyle and overall well-being..

它释放了主动用户对其生活方式和整体福祉做出明智改变的潜力。。

Syai's CGM device pairs with a user-friendly app and cloud-based data solutions that allow patients to track, retrieve, and share real-time data or reports with their healthcare providers or families for more comprehensive care. Syai transformatively positioned data as the core of its CDM strategy, where data-driven analysis & deep learning help improve the quality of life, marking a significant milestone for Syai Health..

Syai的CGM设备与用户友好的应用程序和基于云的数据解决方案相结合，使患者能够跟踪、检索并与医疗保健提供者或家属共享实时数据或报告，以获得更全面的护理。Syai变革性地将数据定位为其CDM战略的核心，数据驱动的分析和深度学习有助于提高生活质量，标志着Syai健康的一个重要里程碑。。

Syai is poised to expand its reach and make its CGM devices available to global customers with the funding. The company's success in investment procurement mentioned is a testament to its prospective for growth and innovation. Regarding the upward trends of self-care and wellness management for individuals over the past few years, Syai's medical devices with advanced software systems are well-positioned to capture a significant portion of the target market and revitalize the CDM (Chronic Disease Management) experiences for customers worldwide.About SyaiHeadquartered in Singapore, Syai Health has emerged as the Transcender of CDM.

Syai准备扩大其业务范围，并通过资金将其CGM设备提供给全球客户。上述公司在投资采购方面的成功证明了其增长和创新的前景。关于过去几年个人自我保健和健康管理的上升趋势，Syai拥有先进软件系统的医疗设备处于有利地位，可以占领目标市场的很大一部分，并为全球客户恢复CDM（慢性病管理）体验。关于Syai总部位于新加坡，Syai Health已成为CDM的超越者。

For more information, visit: http://www.syai.comFor media/business inquiries, please contact: bd@syai.comPhoto - https://mma.prnewswire.com/media/2343276/Syai_Tag_CGM_cross_platform_functionality.jpg .

有关更多信息，请访问：http://www.syai.comFor媒体/商业咨询，请联系：bd@syai.comPhoto-https://mma.prnewswire.com/media/2343276/Syai_Tag_CGM_cross_platform_functionality.jpg。